Human erythrocytes as pharmacological biomodel of antioxidant cytoprotection for the evaluation of new therapeutic alternatives in patients with COVID-19

Authors

Keywords:

pharmacological biomodel, cytoprotection, antioxidant, human erythrocytes.

Abstract

Introduction: The oxidative stress can affect the biological membranes of different cellular types in the organism, which has been evidenced in the damages to the tissues and organs of patients with COVID-19, reason why the recent investigations are related to the search of cytoprotector and antioxidant drugs that minimize these damages. 

Objective: To evaluate the human erythrocytes as pharmacological biomodel of antioxidant cytoprotection.  

Methods: The cytotoxicity pattern was evaluated in erythrocytes induced by peroxide of hydrogen and the system of diagnosis proposed was valued in a cytoprotection assay in erythrocytes, with the use of ascorbic acid as reference substance.  

Results: For the concentration of erythrocytes used a cytotoxicity model was achieved to the concentration of 10 mM of peroxide at 30 minutes of incubation. The substance of reference used didn't show cytotoxicity signs in the hemolysis test. In the cytoprotection assay a pharmacological effect of the referent was evidenced, with a value of the cytoprotection index of 12.71 µg/mL. The study of optic microscopy showed severe morphological damages in the erythrocytes treated with peroxide of spherocytes, echinocytes and spheroechinocytes type that significantly diminished in presence of this reference substance.  

Conclusions: The proposed pharmacological biomodel can be used in the evaluation of new therapeutic alternatives with antioxidant cytoprotector properties for the treatment of patients with COVID-19.  

Downloads

Download data is not yet available.

Author Biography

Irela Yolaidys Pérez Andrés, Centro de Toxicología y Biomedicina, Universidad de Ciencias Médicas. Santiago de Cuba

Directora Centro de Toxicología y Biomedicina. Universidad de Ciencias Médicas. Santiago de Cuba. Cuba

References

1. Casares D, Escribá PV, Rosselló CA. Membrane lipid composition: Effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Mol Sci. 2019 [citado 15/06/2022];20(9):2167. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31052427/

2. Fratta Pasini AM, Stranieri C, Cominacini L, Mozzini C. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants. 2021 [citado 15/06/2022];10(2):272-303. Disponible en: https://www.mdpi.com/2076-3921/10/2/272

3. Vardakas P, Skaperda Z, Tekos F, Kouretas D. ROS and COVID. Antioxidants. 2022 [citado 05/07/2022]; 11(2): 339-341. Disponible en: https://www.mdpi.com/2076-3921/11/2/339

4. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020 [citado 15/07/2022];10(2):1271. Disponible en: https://www.mdpi.com/2039-7283/10/2/1271

5. Barros VA, Pereira GA, Ota SS, Melo F, de Jesus ACS, Lima AB, et al. A theoretical antioxidant mechanism for cytoprotective effect of p-acetamide-salicylate derivatives against free radical initiator AAPH in human erythrocytes. J Braz Chem Soc. 2021 [citado 03/08/2022];32(7). Disponible en: https://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532021000701354

6. Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther. 2020[citado 02/08/2022]; 42(2):116-7. Disponible en: https://www.sciencedirect.com/science/article/pii/S2531137920300298?via%3Dihub

7. Liu W, Li H. Covid-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020 Preprint. https://chemrxiv.org/engage/chemrxiv/article-details/60c74fa50f50db305139743d

8. Pape W. DB-ALM Protocol n° 37: Red Blood Cell (RBC) Test System, 1992 [citado 05/07/2022]. Disponible en: https://jeodpp.jrc.ec.europa.eu/ftp/jrc-opendata/EURL-ECVAM/datasets/DBALM/VER1-0/online/DBALM_docs/37_M_%20Red%20Blood%20Cell%20(RBC)%20Test.pdf

9. Selvaraj S, Krishnaswamy S, Devashya V, Sethuraman S, Maheswari U. Influence of membrane lipid composition on flavonoid–membrane interactions: Implications on their biological activity. Prog Lipid Res. 2015 [citado 05/07/2022];58:1-13. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0163782714000617

10. Gyawali P, Richards RS, Bwititi PT, Nwose EU. Association of abnormal erythrocyte morphology with oxidative stress and inflammation in metabolic syndrome. Blood Cells, Mol Dis. 2015 [citado 05/07/2022];54(4):360-3. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S107997961500025X?via%3Dihub

11.Spengler MI, Svetaz MJ, Leroux MB, Bertoluzzo SM, Parente FM, Bosch P. Lipid peroxidation affects red blood cells membrane properties in patients with systemic lupus erythematosus. Clin Hemorheol Microcirc. 2014 [citado 15/06/2022]; 58(4): 489-95. Disponible en: https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch1716

12. Lopachev AV, Kazanskaya RB, Khutorova AV, Fedorova TN. An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment. Eur J Pharmacol. 2020 [citado 02/08/2022];886. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014299920305495?via%3Dihub

13. Cárdenas Rodríguez N, Bandala C, Vanoye CA, Mejía II, Gómez Manzo S, Hernández Cruz EY. Use of antioxidants for the neuro-therapeutic management of COVID-19. Antioxidants. 2021 [citado 15/07/2022];10(6):971. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34204362/

14. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020 [citado 25/07/2022];24(1):133-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32264963/

15. Coppock D, Violet PC, Vasquez G, Belden K, Foster M, Mullin B, et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life. 2022 [citado 02/08/2022];12(3):453. Disponible en: https://www.mdpi.com/2075-1729/12/3/453

16. Reva I, Yamamoto T, Rasskazova M, Lemeshko T, Usov V, Krasnikov Y, et al. Erythrocytes as a target of SARS-CoV-2 in pathogenesis of COVID-19. Arch Euromedica. 2020 [citado 02/08/2022];10(3):5-11. Disponible en: https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-1005433

17. Kronstein Wiedemann R, Stadtmüller M, Traikov S, Georgi M, Teichert M, Yosef H, et al. SARS-CoV-2 Infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism. Stem Cell Rev Rep. 2022 [citado 03/08/2022];18(5):1809-21. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35181867/

Downloads

Published

2022-10-18

How to Cite

1.
Mora Tassé Y, Fong Lores O, Berenguer Rivas CA, Pérez Andrés IY. Human erythrocytes as pharmacological biomodel of antioxidant cytoprotection for the evaluation of new therapeutic alternatives in patients with COVID-19. MEDISAN [Internet]. 2022 Oct. 18 [cited 2025 Jun. 4];26(5):e4316. Available from: https://medisan.sld.cu/index.php/san/article/view/4316

Issue

Vol. 26 No. 5 (2022): SEPTIEMBRE - OCTUBRE

Section

Original Articles

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.